Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 36NSCLC 9Adenocarcinoma of Lung 5Meningeal Carcinomatosis 4Lung Neoplasms 4Brain Neoplasms 3Respiratory Tract Neoplasms 1Pleural Effusion, Malignant 1Non Small Cell Lung Cancer NSCLC 1Neoplasm, Residual 1Multiple Primary Lung Cancers 1Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non-small Cell Lung Cancer 1EGF-R Positive Non-Small Cell Lung Cancer 1Carcinoma 1Bronchial Neoplasms 1Advanced Non-small Cell Lung Cancer 1Advanced NSCLC Patients With T790M 1Advanced NSCLC 1Advanced Lung Cancer 1Adenocarcinoma 1

Interventions

osimertinib 1durvalumab 1anlotinib 1aflutinib 1Radiosurgery 1Monatide (IMS 3015) 1Immunotherapy 1Docetaxel 1Circulating Tumor DNA 1Chemotherapy, Adjuvant 1Biological Assay 1Adjuvants, Pharmaceutic 1AST5902 1ALT-803 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasm, Residual × aflutinib × Thoracic × Clear all
NCT05079022 2021-10-15

ctDNA-MRD Based Adjuvant Targeted Therapy for EGFR Positive Stage I Lung Adenocarcinomas

Peking University People's Hospital

Phase 1/2 Unknown
50 enrolled
Thoracic

Adenocarcinoma of Lung, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡